The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

Pfizer's Q3 earnings soar on COVID revenue but stock dips as market doubts long-term growth. See why I think that 2025 will not be a strong year for PFE stock.

Pfizer Inc ( (PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

Pfizer, which is under pressure from activist investor Starboard, on Tuesday topped third-quarter estimates as sales of its COVID-19 treatment Paxlovid blew past Wall Street expectations. The U.S.

Portfolio manager Dave Wagner stressed the need for further cost management and streamlined operations. With optimistic ...

Pfizer Inc. (NYSE: PFE) has reported a robust financial performance for the third quarter of 2024, showcasing significant growth across its product portfolio. The pharmaceutical giant’s revenues ...